CN108720013A - The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract - Google Patents
The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract Download PDFInfo
- Publication number
- CN108720013A CN108720013A CN201810468910.0A CN201810468910A CN108720013A CN 108720013 A CN108720013 A CN 108720013A CN 201810468910 A CN201810468910 A CN 201810468910A CN 108720013 A CN108720013 A CN 108720013A
- Authority
- CN
- China
- Prior art keywords
- fructose
- formula
- tea
- tea extract
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005715 Fructose Substances 0.000 title claims abstract description 95
- 229930091371 Fructose Natural products 0.000 title claims abstract description 94
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 title claims abstract description 94
- 239000000284 extract Substances 0.000 title claims abstract description 51
- 238000012545 processing Methods 0.000 title claims abstract description 21
- 235000013402 health food Nutrition 0.000 title claims abstract description 15
- 241001122767 Theaceae Species 0.000 title abstract 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 151
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000013078 crystal Substances 0.000 claims abstract description 37
- 210000004185 liver Anatomy 0.000 claims abstract description 33
- 235000019441 ethanol Nutrition 0.000 claims description 94
- 244000269722 Thea sinensis Species 0.000 claims description 89
- 235000013616 tea Nutrition 0.000 claims description 87
- 239000000843 powder Substances 0.000 claims description 30
- 235000013824 polyphenols Nutrition 0.000 claims description 29
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 230000002829 reductive effect Effects 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 235000006468 Thea sinensis Nutrition 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- 235000013361 beverage Nutrition 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 16
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 16
- 229910052782 aluminium Inorganic materials 0.000 claims description 10
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 10
- 239000004411 aluminium Substances 0.000 claims description 10
- -1 filtering Substances 0.000 claims description 10
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 claims description 9
- 238000005538 encapsulation Methods 0.000 claims description 9
- 235000020333 oolong tea Nutrition 0.000 claims description 9
- 235000020339 pu-erh tea Nutrition 0.000 claims description 9
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 8
- 235000020279 black tea Nutrition 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 8
- 229960003080 taurine Drugs 0.000 claims description 8
- 235000021433 fructose syrup Nutrition 0.000 claims description 7
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 7
- 235000019136 lipoic acid Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229960002663 thioctic acid Drugs 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- 235000009569 green tea Nutrition 0.000 claims description 6
- 238000010025 steaming Methods 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 229940026510 theanine Drugs 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 229940094952 green tea extract Drugs 0.000 claims description 3
- 235000020688 green tea extract Nutrition 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 230000002075 anti-alcohol Effects 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- PHRUYNFFDRXZQY-UHFFFAOYSA-N [S].C(CCCCCCC)(=O)O Chemical compound [S].C(CCCCCCC)(=O)O PHRUYNFFDRXZQY-UHFFFAOYSA-N 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 230000006837 decompression Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 35
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 16
- 210000003734 kidney Anatomy 0.000 abstract description 15
- 230000004060 metabolic process Effects 0.000 abstract description 15
- 102000007698 Alcohol dehydrogenase Human genes 0.000 abstract description 11
- 108010021809 Alcohol dehydrogenase Proteins 0.000 abstract description 11
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 230000007774 longterm Effects 0.000 abstract description 9
- 230000035622 drinking Effects 0.000 abstract description 8
- 230000001476 alcoholic effect Effects 0.000 abstract description 7
- 231100000753 hepatic injury Toxicity 0.000 abstract description 6
- 210000005239 tubule Anatomy 0.000 abstract description 6
- 230000002440 hepatic effect Effects 0.000 abstract description 5
- 230000003902 lesion Effects 0.000 abstract description 5
- 206010067125 Liver injury Diseases 0.000 abstract description 4
- 230000001133 acceleration Effects 0.000 abstract description 4
- 230000002503 metabolic effect Effects 0.000 abstract description 4
- 208000034189 Sclerosis Diseases 0.000 abstract description 3
- 206010039203 Road traffic accident Diseases 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000029142 excretion Effects 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 39
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 39
- 229940116269 uric acid Drugs 0.000 description 39
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 26
- 241000700159 Rattus Species 0.000 description 22
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 13
- 229960001948 caffeine Drugs 0.000 description 13
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 208000007848 Alcoholism Diseases 0.000 description 10
- 108010093894 Xanthine oxidase Proteins 0.000 description 10
- 102100033220 Xanthine oxidase Human genes 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 201000007930 alcohol dependence Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 235000014101 wine Nutrition 0.000 description 8
- 108010078791 Carrier Proteins Proteins 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 108091006303 SLC2A9 Proteins 0.000 description 6
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 6
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000009103 reabsorption Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 244000062793 Sorghum vulgare Species 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- ZKLLSNQJRLJIGT-UYFOZJQFSA-N keto-D-fructose 1-phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O ZKLLSNQJRLJIGT-UYFOZJQFSA-N 0.000 description 4
- 235000019713 millet Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 240000006394 Sorghum bicolor Species 0.000 description 3
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003158 alcohol group Chemical group 0.000 description 3
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108010025188 Alcohol oxidase Proteins 0.000 description 2
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 2
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 2
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 206010023424 Kidney infection Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000001105 Phosphofructokinases Human genes 0.000 description 2
- 108010069341 Phosphofructokinases Proteins 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003683 cardiac damage Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 235000019137 high fructose diet Nutrition 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000001343 mnemonic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- ASUMVAPLXCRBMA-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(2,3-dihydro-1,4-benzoxazin-4-yl)methanone Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2OCC1 ASUMVAPLXCRBMA-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 102000003793 Fructokinases Human genes 0.000 description 1
- 108090000156 Fructokinases Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940083914 URAT1 inhibitor Drugs 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960003838 lesinurad Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000001570 microsomal oxidation Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940092665 tea leaf extract Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000020334 white tea Nutrition 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
- 229940032415 zurampic Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The formula and processing technology of the health food for the Soboring-up liver-protecting that the present invention relates to one group to be made of fructose and tea extract.Long-term heavy drinking can lead to alcoholic liver injury, hepatic sclerosis etc., it is also the major reason for causing traffic accident to drive when intoxicated, has effects that the health food of Soboring-up liver-protecting by what fructose and tea extract formed the invention discloses one group, the product can be solved due to drunk caused by heavy drinking in daily life, lesions of liver and kidney and central lesion etc..The characteristics of fructose drunkenness dispelling tea of the present invention is the high proportion that crystal diabetin accounts for 85~95% in formula, and tea extract accounts for 3~15%；Fructose can in acceleration bodies alcohol metabolism, alcohol is promoted to be discharged through kidney rapidly, tea extract can enhance the activity of alcohol dehydrogenase, the metabolic conversion of acceleration of alcohol, while tea extract can inhibit re-absorption of the renal tubule to alcohol, promote the excretion of alcohol, internal alcohol concentration is set to reduce rapidly, to produce Quick sobering effect, hyperuricemia also has prevention effect caused by tea extract is possible to fructose, and good effect is obtained through zoopery and human body application.
Description
Technical field
The invention belongs to the technical fields of food and health food production, and in particular to one group by fructose and tea extract
The formula and processing technology of the health food and drug with Soboring-up liver-protecting of composition.
Background technology
Long-term heavy drinking can lead to alcoholic liver injury, this is a kind of very common one in the crowd to drink throughout the year
Kind of liver diseases, the spirits culture in China is of long standing and well established, and " urging the guests to drink " is behavior warmhearted and hospitable on the dining table of Chinese.Heavy drinking
Since alcohol Excess free enthalpy causes oxidative pressure in liver, oxidative and anti-oxidative system is unbalance, causes alcoholic liver injury.Alcohol
The incidence of liver is closely related with improvement of living standard.It is also the common disease of the developed countries such as America and Europe.But it is close several
Year advancing by leaps and bounds with China's level of economic development, variation with rapid changepl. never-ending changes and improvements also has occurred in people's lives level, daily
The consumption of the alcoholic drinks such as white wine, beer, red wine also increases considerably in diet, relevant disease caused by alcohol and problem day
It is beneficial serious, such as：Alcoholic liver disease incidence rises rapidly, and according to statistics, alcoholic cirrhosis patient onset of liver cancer rate is more than 50%,
In the low area of hepatites virus infections rate, it is addicted to drink and has become the main reason for causing liver cancer；Chronic alcoholism can cause mnemonic learning
Ability decline, polyneuropathy, chronic gastritis, cardiac damage and organic psychosis etc.；It drives when intoxicated caused traffic
Accident is always a public health problem, and therefore, the research with alcohol-related problem is constantly subjected to pay much attention to.Investigation hair
Existing, alcoholic liver is increasingly becoming the main inducing of hepatic sclerosis, and there are about the experience that 60% has long-term excessive consumption of alcohol in patient with liver cirrhosis.Separately
On the one hand, the morbidity crowd of alcoholic liver is based on the young and the middle aged, and 80% alcohol hepatopath was at 40 years old or so.It is estimated that the whole world is indulged in
Up to 15,000,000~20,000,000 people of wine crowd, wherein the different Alcoholic of degree has been caused in 10%~20% (1,500,000~4,000,000)
Hepatopathy.Corresponding in this, the morbidity crowd of the liver diseases such as fatty liver, hepatic sclerosis caused by long-term excessive consumption of alcohol is expanding increasingly
Greatly, the death rate caused by severe cirrhosis is also riseing increasingly, causes the extensive concern of domestic and international medical field.
Studies have shown that alcoholic liver disease is a kind of pathologic process of complexity, be secondary to alcohol after liver metabolism
It generates, there are about 20% -25% ethyl alcohol can enter human body after people drink, wherein 90% or more is metabolized in liver
, remaining then excretes human body quickly by human body by breathing or urine, the form of excrement.And absorption of human body ethyl alcohol is main
Organ is stomach and small intestine, includes cell in alcohol dehydrogenase (ADH), acetaldehyde dehydrogenase (ALDH), microsomal ethanol oxidase system
It is metabolized under the participation of cytochrome p 450 2E1 (CYP450 2E1).About 80% ethyl alcohol generates second through alcohol dehydrogenase enzyme effect
Aldehyde, then acetic acid is generated through acetaldehyde-dehydrogenase enzyme effect, it is reacted subsequently into oxidation cycle, final metabolism generates carbon dioxide and water,
It is another to have about 20% ethyl alcohol then by the CYP450 2E1 metabolism of microsome, also small part with original shape through respiratory tract, urine, sweat
It is expelled directly out.
Alcohol dehydrogenase is distributed mainly on gastrointestinal tract and liver, and ethyl alcohol can reduce body to ethyl alcohol in the first-pass metabolism of stomach
Bioavilability, alleviate ethyl alcohol to the toxic effects of the organs such as liver, brain.Long-term heavy drinking will lead to stomach alcohol dehydrogenase
Enzymatic activity progressive declines, and then progressive increases L-AD activity.After ethyl alcohol enters liver cell, mainly pass through
Three kinds of different metabolic pathways are oxidized to acetaldehyde.Alcohol dehydrogenase is the important enzyme that alcohol metabolism is participated in liver, in wine
It plays a significant role in the metabolism and utilization of essence.And the ethyl alcohol generated then produces second by the catalysis deamination of acetic acid deaminase
Acid.Acetic acid enters tricarboxylic acid cycle with the help of acetyl coenzyme A.Ethyl alcohol is finally metabolised to CO2And discharge ATP.In addition it crosses
Hydrogen oxide body catabolic enzyme and microsomal oxidation enzyme system also play a role in the metabolism of alcohol.In general, alcohol exists
Internal metabolism mainly carries out dehydrogenation oxidation effect through Alcohol Dehydrogenase and catalase and generates acetaldehyde, in the two approach
Oxygen radical can be activated.Oxidative damage caused by free radical is considered as the basic pathology machine of one of alcoholic liver injury
System.The acetaldehyde that oxidation of ethanol generates has significant toxicity to liver cell, the severe jamming normal physiological function of liver cell.In second
Under the long-term murder by poisoning of aldehyde, liver cell is easy to denaturation and necrosis, and cell activity is gradually reduced, or even loses, and fiber then occurs
Change.If developed as one pleases, liver will harden when serious.
It is clinically that gastric lavage, fluid infusion, replenishing vitamins are taken to patient about the conventional treatments of acute alcoholism
On the basis of the treatments such as diuresis, it was divided into for three phases by alcoholism weight, gives the naloxone of various dose respectively, it can specificity
Blocking intracerebral opiate receptor and reduce Content of B-ep, play therapeutic effect to acute alcoholism.Domestic solution at present
The Mechanism Study of yeast for brewing rice wine object is primarily referred to as, by increasing the activity of alcohol dehydrogenase in liver and stomach, enhancing the first-pass metabolism of ethyl alcohol
And blood alcohol concentration is reduced, to mitigate its damaging action to organs such as liver, brains.In the compound of traditional Chinese medicine and primary extract side
Face, such as Compound hyperosmotic solution, flower of kudzuvine, hoveniae semoveniae semen water extract, Ganlan Jiejiuyin.Rich in polyphenol compound, purine in tealeaves
Alkaloid, multivitamin and amino acids substance solve alcoholism with tea, this is that people are familiar with and extensive use already
In the common sense of daily life.How on the books this is in China's successive dynasties medical literature.Such as《A Supplement to the Compendium of Materia Medica》,《Renzhai Zhi Zhi Fang, Effective Recipes from Renzhai House》
Deng referred to as " relieving the effect of alcohol ".The Qing Dynasty《Essentials of Materia Medica》In, just there is the note of " tea has solution food and drink, the greasy, poison burned, sharp stool and urine "
It carries, tea polyphenols, theophylline, xanthine, caffeine, tea glucoside, flavonoids organic acid, a variety of amino acid and a variety of dimensions contained in tealeaves
The substances such as raw element, mutual compatibility, " amethystic agent " for keeping for example same auxiliary taste of millet paste complete.Its main function is " excited maincenter
Nerve fights the inhibiting effect of gentle solution alcohol；Blood vessel is expanded, blood circulation is conducive to；Improve liver metabolism ability；Diuresis promotees
It is discharged into alcohol from rapid in vivo.Experiment shows the re-absorption that the diuresis of tea inhibits renal tubule to alcohol, can reinforce
The resistance infection of kidney local immunity ability and urinary system.Tea neither inhibits nerve, also not damaging work(during relieving the effect of alcohol
Energy.All it is useful and harmless so drinking tea after drinking no matter in terms of theoretical or practice.
In addition, the problem drunk about strong tea solution is drunk, also there is different opinions, it is believed that no matter which kind of wine, it is therein
Main component is all alcohol (ethyl alcohol).Alcohol content in wine is higher, bigger to the harm of human body.Excessive consumption of alcohol can cause urgency
Property alcoholism, i.e., it is drunk.Although the caffeine in tealeaves has diuresis, can accelerating alcohol discharge, by urine ejection
Ethyl alcohol total amount is seldom, is no more than the 3% of drink amount.This is because drink into the ethyl alcohol of wine 90% can be metabolized to water and dioxy in vivo
Change carbon, the only ethyl alcohol less than 10% is discharged by urine, sweat, saliva and breathing, and the caffeine in millet paste can not neutralize wine
In ethyl alcohol.The technical journal in the U.S. was also once pointed out：" many people believe or wish that caffeine plays the role of fighting alcohol.Due to
This idea, caffeine is once to treat alcoholism and drunk, but actually alcohol has with the effect of caffeine and is added
Property." summation action caused by caffeine and ethyl alcohol cannot not only sober up, can aggravate instead drunk.In addition, the caffeine in tea
Content is about the 2~5% of dry matter, when brewing there are about 80% caffeine can dissolve deposit in millet paste, in usual one or two cup of millet paste
Just contain 150~250 milligrams of caffeine.Caffeine content in strong tea is relatively high, and being drunk when drunk can intense stimulus kidney；
Simultaneously because caffeine is strong central nervous excitation agent, the coffee alkali number in strong tea is larger, can cause entire maincenter god
Extremely excited through system, drunk person is likely to occur clonic convulsion and dead.In addition, the ethyl alcohol overwhelming majority in wine is needed in liver
Dirty middle processing, ethyl alcohol first resolves into acetaldehyde through alcohol dehydrogenase enzyme effect, and acetaldehyde need to could divide under the action of aldehyde dehydrogenase
Xie Chengshui and carbon dioxide.Strong tea is drunk in the case of drunk, since the stronger diuresis of strong tea makes acetaldehyde also have little time to convert
Salt water and carbon dioxide have just hurried into kidney, lead to direct stimulation and damage of the acetaldehyde to kidney.In recent years research shows that
Tea extract can eliminate mouse excited dry dynamic and incoordination phenomenon caused by drunk, have sobering-up functions, and the effect
Unrelated with Tea Caffeine, tea polyphenols can effectively inhibit the excitability of ethyl alcohol mouse, reduce its ataria ability, improve its second
Alcohol median lethal dose prompts tea polyphenols to have antialcoholism action, also studies have shown that tea polyphenols are good free radical scavengers,
Tea polyphenols have the function of that anti-oxidant, anti-apoptotic, radioresistance, antitumor, neuroprotection and pre- preventing bone rarefaction, someone report tea
Polyphenol has preferable prevention effect to the Sperm lesion after alcoholism, to the degradation organ liver of alcohol, also has to a certain degree
Protective effect.They are by detecting the level of SOD, MDA, ROS, GSH-px in serum AST, ALT and hepatic tissue and exempting from
Epidemic disease groupization observes liver cell histopathology morphologic change, it was demonstrated that tea polyphenols are in alcoholic liver damage mouse liver cell
Bcl-2 positive expressions are substantially reduced to improve significantly with the equal apparent increase of Bax positive expressions, prompts in Chronic Alcohol
Poison can cause hepatic injury, and degree of injury can be mitigated by feeding tea polyphenols, and alcohol group murine liver tissue ROS is also observed in experiment,
The horizontal conspicuousnesses of MDA increase, and antioxidase glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) are living
Property reduce.Murine liver tissue ROS, the MDA level for giving tea polyphenols+alcohol is substantially less than alcohol group, and GSH-Px, SOD activity are bright
It is aobvious to be higher than alcohol group.As a result it prompts, alcohol metabolism not only creates a large amount of active oxygen radical in liver cell and causes lipid
Peroxidating, and lead to the reduction of Antioxidant Enzyme Systems activity, it is in oxidative stress state, and tea polyphenols aoxidize hepatic tissue caused by alcohol
Stress have and be relieved effect.（Tang Yinjuan, the experimental study that tea polyphenols influence chronic alcoholism hepatic injury, China faces
Bed Chinese Journal of anatomy the 2nd phase of volume 34 in 2016：198~201）.
Crystal diabetin is a kind of hexose of levorotation, and fructose is into can be with intestinal epithelial cell carrier protein after everybody body
In conjunction with being absorbed into human body, metabolism in vivo is participated in the effect of specific fructokinase in liver, kidney, small intestine.The oral ratio of fructose
Glucose absorption is slow, but is metabolized after absorbing or in vivo faster than glucose after intravenously administrable, is easily absorbed by organisms utilization, and not
Insulin is relied on, small to blood sugar influence, the patient for being suitable for glucose metabolism and dyshepatia supplements energy.Into in human body
Fructose can generate fructose-6-phosphate by the catalysis of hexokinase, and enter glycolysis.In liver, fructose passes through liver fructose
Kinases and aldolase B effect, dihydroxyacetone phosphate and glyceraldehyde are cracked by fructose-1-phosphate, and the latter swashs through glyceraldehyde
Enzymatic is transformed into glyceraldehyde-3-phosphate.Dihydroxyacetone phosphate and glyceraldehyde-3-phosphate can participate in glycolysis or gluconeogenesis way
Diameter.Fructose is fast to alcohol resolution, is suitble to relieve the effect of alcohol, and obtaining for this conclusion is published in derived from nineteen eighty-three Jones AW《Med
Biol.1983;61(6):319-23.》On paper, which draws a conclusion：Fructose is that a kind of anti-blood alcohol increases and most has
The sugar of effect, it has the synergistic effect for delaying alcohol absorption and accelerating alcohol removing.Experiment shows absorptance of the human body to alcohol
The absorption of other foods much faster, after alcohol absorption enters blood, relies primarily on ethyl alcohol enzymatic into its oxygenolysis.Ethyl alcohol enzyme
Oxygenolysis alcohol needs energy, energy directly ATP to be relied on to provide.Glucose and fructose can provide ATP, but they provide and divide
The help of glucose phosphate kinases and phosphofructokinase is not needed.Glucose needs first to irritate insulin secretion, supports to improve
The activity of Glucose Liquid kinases could be generated relatively slowly and help alcohol oxidase decomposing alcohol.And phosphofructokinase
It is active high, and the auxiliary of insulin is not depended on, therefore, fructose can provide rapidly a large amount of ATP and go that alcohol oxidase is helped to decompose
Alcohol.Also researcher observes that adult female rats add 10 days after fructose in its drinking water, and ethyl alcohol elimination factor is aobvious
It writes and improves, rat ethyl alcohol clearance rate is increased to (4.85 ± 0.28) mmolL-1 (ethyl alcohol) min-1·g-1 (liver weight), and
No fructose control group is (3.65 ± 0.29) mmolL-1(ethyl alcohol) min-1·g-1(liver weight), prompts supplemental fructose to increase
The strong elimination of ethyl alcohol, but there is no the activity for changing alcohol dehydrogenase.In another pair and the relevant peroxidating of alcohol metabolism
In the research of hydrogen enzyme, 2gkg is also demonstrated-1Fructose injection can stimulate mouse alcohol metabolism, but large dosage (10gkg-1) then may be used
Alcohol metabolism is blocked, to further affirm that fructose has the function of sobering up under doses by zoopery.Fructose
Excess free enthalpy will also result in many adverse reactions, such as may occur in which dyslipidemia, fatty liver, insulin resistance, weight increase, blood
Pressure increases and the performances such as hyperuricemia, generation caused by this symptom related with metabolic effect is known as fructose Excess free enthalpy excessively
Thank to syndrome.Have been reported that the fructose intake in day dietary amount more than 20% can cause the male individual of high blood insulin levels
Blood triglyceride, total cholesterol, low density lipoprotein cholesterol increase；Animal experimental observation can induce liver to high fructose diet
Lipidosis, short-term and long-term high Fructose-Fed can lead to rodent fatty liver, but the phenomenon is in human research
Middle observation is confirmed not yet；Epidemiological study finds that the intake of fructose and serum Uric Acid Concentration are significantly correlated, i.e., high agent
The fructose of amount can cause uric acid to increase, and find that the intake of fructose is related to hyperuricemia by Liang Xiang prospective cohort studies
Property disease gout is also related to kidney stone, and the result of zoopery is consistent with human research, therefore, largely take fructose it is noted that
Uric acid is detected, the generation of gout and kidney stone is prevented.
The main component tea polyphenols of tea extract, especially tealeaves have hyperuricemia caused by fructose apparent pre-
Anti- effect has research researcher to apply and drinks 10g/100mL fructose solns induction hyperuricemia rat model, discovery 150,
300 mg/（kg·d）Tea polyphenols can significantly reduce hyperuricemia rat serum uric acid level, while 150,300 mg/（kg·d）
Tea polyphenols also significantly reduce expression and the vigor of liver xanthine oxidase, hence it is evident that reduce URAT1, GLUT9 in kidney and express
It is expressed with UAT is increased.Today's society hyperuricemia incidence increases and year by year under the apparent background of rejuvenation trend, height urine
Acidaemia study of incident mechanism and medicine research and development become current popular research field, are urinated about high fructose diet and mankind's height
Whether the high incidence of acidaemia is related, is still debating endlessly so far, but drinks the rat of 10g/100mL fructose solns feeding
It has become and is widely used in establishing one of method of hyperuricemia model now.Swashed by fructose in the fructose of liver, absorption
Enzyme tachymetabolism becomes fructose 1-phosphate.Then aldolase B catalysis fructose 1-phosphate is finally metabolized as aliphatic acid and carbon dioxide.
Fructose metabolism is that consume a large amount of atriphos during fructose 1-phosphate be adenosine diphosphate (ADP), causes adenosine monophosphate and flesh
Nucleotide levels increase.The two can generate hypoxanthine and xanthine afterwards, finally be metabolized as uric acid under xanthine oxidase effect.
In this experiment, for feeding rat 10g/100 mL fructose solns after 8 weeks, rat serum uric acid level is more aobvious than control group rat height
Work increases.Give clinically used anti-trioxypurine drug allopurinol treatment 4 weeks, rat serum uric acid level significantly reduces, close pair
According to a group rat uric acid level.Uric acid is purine base end product of metabolism, and xanthine oxidase is that xanthine is mediated to be metabolized as uric acid
Key enzyme, in human body, xanthine oxidase are primarily present in liver, are present in other histoorgans such as enteron aisle on a small quantity, so,
Liver is the main workshop of body uric acid, and regulation and control liver xanthine oxidase activity can significantly reduce serum uric acid level, face
Common treatment antihyperuricemic the disease drug such as allopurinol, Febustat of bed, is xanthine oxidase inhibitor, is confirming
After tea polyphenols can reduce the hyperuricemia rat serum uric acid level of 10g/100mL fructose solns induction, which also sees
Tea polyphenols are examined on the expression of liver xanthine oxidase and active influence, the angle generated from regulation and control uric acid inquires into tea polyphenols drop
The potential mechanism of uric acid.As a result, it has been found that feeding rat 10g/100mL fructose solns are after 8 weeks, rat liver xanthine oxidase is lived
Power and the equal highly significant of expression quantity are higher than control group.After giving allopurinol or awarding tea polyphenols, hyperuricemia rats'liver
Dirty xanthine oxidase vigor and the equal highly significant of expression reduce, and there were significant differences compared with hyperuricemia group rat.These
The result shows that GTP reduces 10g/100mL fructose solns induction hyperuricemia rat serum uric acid level, inhibits liver xanthine
Oxidase active and expression, it is closely related to reduce uric acid generation.In addition, the uric acid about 70% that body generates is arranged by kidney
Let out, remaining 30% is drained by alimentary canal, blood uric acid almost all with prototype through glomerular filtration, but the uric acid 98% filtered~
100% in renal tubule by reabsorption, be then secreted into renal tubule again, excreted finally by urine.URAT1 and GLUT9 is two
A important transhipment for mediating uric acid in reabsorption, is mainly expressed in renal cells.Uric acid in renal tubule
It is transported in epithelial cell by the URAT1 on renal cells teleblem, then by renal cells
GLUT9 is transported to renal interstitial, a kind of nearest new anti-trioxypurine drug Zurampic tablets（Lesinurad, URAT1 inhibitor）?
The U.S. goes through to list, and has highlighted important function of the regulation and control kidney uric acid transporter subfunction in maintaining body uric acid stable state.Urine
Sour specific transporters are enriched in kidney is expressed in proximal tubule tune and liter section, and reabsorption enters the uric acid nearly 50% of blood
Tube chamber is secreted by its mediation, is excreted with urine.Therefore, uric acid specific transporters are acknowledged as maintaining body blood urine
The important adjusting factor of sour stable state.In this study, compared with the control rats of normal water, 10g/100mL fructose is given
There is the raising of expression quantity highly significant, and uric acid specific transporters table in rat kidney URAT1 and GLUT9 after solution 8 weeks
Up to amount, then highly significant reduces, and prompts to drink 10g/100mL fructose solns induction of rat kidney uric acid metabolism disorder, i.e., inhales again
It receives and increases, secretes and reduce, eventually led to the notable raising of serum uric acid level.After giving tea polyphenols treatment, hyperuricemia group
URAT1 and GLUT9 expression significantly reduces in rat kidney, and uric acid specific transporters expression quantity dramatically increases.On
Hyperuricemia rat blood uric acid can be reduced by reducing uric acid reabsorption and enhancing uric acid secretion by stating result prompt tea polyphenols
It is horizontal.The experimental results showed that 150,300 mg/（kg·d）Tea polyphenols can reduce the high lithemia of 10g/100mL fructose solns induction
Mass formed by blood stasis rat serum uric acid level, mechanism both with inhibit xanthine oxidase mediate uric acid generations it is related, also with regulate and control URAT1
The uric acid secretion mediated with the GLUT9 uric acid reabsorptions mediated and uric acid specific transporters is closely related.It is more using tea
Phenol researches and develops new anti-trioxypurine health product and provides experimental basis【Chen Gang, the hyperuricemia rat that tea polyphenols induce fructose
The influence of serum uric acid level and mechanism, Food Science, 2017,38（23）：219~223】.
Invention content
This project applicant proposes that the health care that one group formed with fructose and tea extract has effects that Soboring-up liver-protecting is eaten
Product, to solve due to drunk caused by heavy drinking in daily life, lesions of liver and kidney and central lesion, and it is long-term
Excessive drinking causes the decline of mnemonic learning ability, polyneuropathy, chronic gastritis, cardiac damage and organic psychosis etc..This hair
The bright fructose refers to crystal diabetin, also includes fructose syrup, the high fructose syrup for being especially 55~78% containing fructose, tea
Leaf extract refers to black tea extract, also includes green tea, oolong tea, Pu'er tea, the extract of white tea and black tea, fruit of the invention
The sober up formula rate crystal diabetin of tea composition of sugar accounts for 85~95%, and tea extract accounts for 3~15%；The tealeaves extraction of the present invention
Object can also use the active constituent substitution of the tealeaves such as tea polyphenols, theanine, glutamic acid and asparatate.Present invention application fructose
The metabolism of alcohol in acceleration bodies, can be such that the alcohol in blood is excreted through kidney rapidly, and tea extract can promote ethyl alcohol de-
The activity of hydrogen enzyme, the metabolic conversion of acceleration of alcohol, while the diuresis of tea inhibits re-absorption of the renal tubule to alcohol, also may be used
To reinforce the resistance infection of kidney local immunity ability and urinary system, the two has played difference in alcohol different metabolic approach
Comprehensive function internal alcohol can be made quickly from internal discharge, the concentration of internal alcoholism to be made to reduce rapidly, to
Produce Quick sobering effect.In addition, tea extract and tea polyphenols to the hyperuricemia of fructose also have it is apparent prevent and
Antagonism, avoid widely apply fructose it is possible that adverse reaction.The fructose that the present invention prepares is sobered up tea product, is led to
The drunk experiment for carrying out mouse using commercially available 56% 2 steamed bread of corn wine is crossed, 56 degree of Red Star strong, colourless liquor distilled from sorghum are given according to mouse weight
0.15ml/10g is administered 100% mouse in 1 hour and drunk performance all occurs（Righting reflex loss）, and award 56 degree it is red
Give within 30 minutes before star strong, colourless liquor distilled from sorghum fructose drunkenness dispelling tea, the not liquor-saturated rate of mouse reaches 57.2%, individually gives fructose or individually give
Tea extract, the not liquor-saturated rate of mouse are respectively 14.3% and 28.6%, meanwhile, drunk strong, colourless liquor distilled from sorghum control group average out to of holding time
221 minutes, fructose drunkenness dispelling tea average out to 127 minutes, when individually giving fructose or individually giving the drunk maintenance of tea extract
Between be respectively 212 and 264 minutes, compared with the control group, drunk hold time shortens 57.4% to fructose drunkenness dispelling tea, illustrates fruit
Sugared drunkenness dispelling tea has apparent sobering-up functions really.
Specific implementation mode：
The following is specific embodiments of the present invention, and technical scheme of the present invention is further described, but the guarantor of the present invention
Shield range is not limited to these examples, every to be included in the present invention's without departing substantially from the change of present inventive concept or equivalent substitute
Within protection domain.
Embodiment one
Prepare the formula and processing technology of fructose Soboring-up liver-protecting black tea：Formula：3~10kg of black tea extract, crystal diabetin 90
kg；Production technology is that first black tea is crushed first to use ultrasound according to the ethyl alcohol of the ratio addition 75% of solid-liquid ratio 1: 25 for coarse powder
Extraction method is extracted, ultrasonic power 200W, and Extracting temperature is 70 DEG C, and extraction time is 30 min, is filtered while hot, filtrate recycling
Ethyl alcohol is simultaneously concentrated into relative density 1.30~1.32, is dried under reduced pressure, is ground into fine powder；Filter residue adds water boiling twice, first time 2
Hour, second 1.5 hours, merging steaming liquid, filtering, filtrate is concentrated into the clear cream of relative density 1.30~1.32, is dried under reduced pressure,
It is ground into fine powder, two kinds of fine powders are merged, by 3~10:90 ratio is uniformly mixed with crystal diabetin, is packed as 10~12g/
Packet, aluminium film encapsulation to get.
Embodiment two
Prepare the formula and processing technology of fructose protect liver green tea：Formula：3 ~ 10kg of green-tea extract, 3 ~ 10kg of taurine,
95 kg of crystal diabetin；Production technology is that green tea crushing is coarse powder, according to the ratio distilled water of solid-liquid ratio 1: 40, control extraction
Temperature is 70 DEG C, extracts 90min, and filtering retains filtrate, and filter residue is primary by the extraction of preceding method again, retains filtrate, and merging is filtered twice
Liquid, filtrate are concentrated into the clear cream that relative density is 1.30 ~ 1.32, are dried under reduced pressure, are ground into fine powder；Filter residue is according to solid-liquid ratio 1: 20
Ratio addition 75% ethyl alcohol, being 70 DEG C in temperature makes heating and refluxing extraction, and extraction time is 50 min, is filtered while hot, filtrate
Recycling ethyl alcohol is simultaneously concentrated into relative density 1.30 ~ 1.32, is dried under reduced pressure, is ground into fine powder；Two kinds of fine powders are merged, are carried by green tea
It takes object 3 ~ 10, the ratio of taurine 3 ~ 10, crystal diabetin 85 ~ 95 to be uniformly mixed with crystal diabetin, is packed as 10 ~ 12g/ packets, aluminium
Film encapsulation to get.
Embodiment three
Prepare the formula and processing technology of fructose oolong tea：Formula：3 ~ 10kg of oolong tea extract, 3 ~ 10kg of lipoic acid, knot
Brilliant 85 ~ 95kg of fructose；It is coarse powder that production technology, which is oolong tea crushing, according to the second of the ratio addition 75% of solid-liquid ratio 1: 25
Alcohol is extracted with ultrasonic extraction, ultrasonic power 200W, and Extracting temperature is 70 DEG C, and extraction time is 30 min, is filtered while hot,
Filtrate recycling ethanol is simultaneously concentrated into relative density 1.30 ~ 1.32, is dried under reduced pressure, is ground into fine powder；Filter residue adds water boiling twice,
2 hours for the first time, second 1.5 hours, merging steaming liquid, filtering, filtrate is concentrated into the opposite clear cream for density 1.30 ~ 1.32,
It is dried under reduced pressure, is ground into fine powder, by oolong tea extract 3 ~ 10, lipoic acid 3 ~ 10, ratio and the crystallization fruit of crystal diabetin 85 ~ 95
Sugar is uniformly mixed, and is packed as 10 ~ 12g/ packets, aluminium film encapsulate to get.
Example IV
Prepare the formula and processing technology of fructose Pu'er tea：Formula：3 ~ 10kg of Pu'er tea, 3 ~ 10kg of taurine,
3 ~ 10kg of lipoic acid, 85 ~ 95 kg of crystal diabetin；Production technology is that first Pu'er tea is crushed is coarse powder, according to solid-liquid ratio 1:
The ethyl alcohol of 25 ratio addition 75%, 40 min of refluxing extraction when temperature is 70 DEG C are filtered, filtrate recycling ethanol is simultaneously dense while hot
It is reduced to relative density 1.30 ~ 1.32, is dried under reduced pressure, fine powder is ground into；Filter residue adds water boiling twice, 2 hours for the first time, and second
Secondary 1.5 hours, merge steaming liquid, filtering, filtrate is concentrated into the clear cream of relative density 1.30 ~ 1.32, is dried under reduced pressure, and is ground into thin
Powder is mixed by the ratio of Pu'er tea 3 ~ 10, taurine 3 ~ 10, lipoic acid 3 ~ 10, crystal diabetin 85 ~ 95 with crystal diabetin
Uniformly, be packed as 10 ~ 12g/ packets, aluminium film encapsulation to get.
Embodiment five
Prepare the formula and processing technology of fructose Antialcoholic tea：Formula：2 ~ 5kg of tea polyphenols, 1 ~ 2kg of theanine, glutamic acid 1 ~
2kg, 1 ~ 2kg of asparatate, 85 ~ 95 kg of crystal diabetin；Production technology is first each ingredient in formula and crystallization
Fructose is uniformly mixed, and is ground into fine powder, is packed as 10 ~ 12g/ packets, aluminium film encapsulate to get.
Embodiment six
Prepare the formula and processing technology of fructose alcohol-decomposing beverage：Formula：2 ~ 5kg of tea polyphenols, 1 ~ 2kg of theanine, glutamic acid 1
~ 2kg, 1 ~ 2kg of asparatate, 85 ~ 95 kg of crystal diabetin；Production technology is first each ingredient in formula and crystallization
Fructose is dissolved in the clean water that can be used as beverage application, is uniformly mixed, the concentration of fructose is made to reach 8 ~ 10%, it is packed as 150 ~
250ml/ bottles, encapsulation to get.
Embodiment seven
Prepare the formula and processing technology of fructose and the alcohol-decomposing beverage of tea extract composition：Formula：Tea extract 3 ~
8kg, 90 ~ 95 kg of crystal diabetin；Production technology is that tea extract and crystal diabetin are dissolved in can be used as beverage application
Clean water in, be uniformly mixed, the concentration of fructose made to reach 8 ~ 10%, be packed as 150 ~ 250ml/ bottle, encapsulate to get.The technique
Tea extract can be prepared according to the method for one of above-described embodiment, can also be prepared with other existing techniques, with knot
Brilliant fructose is prepared into beverage.
Embodiment eight
Prepare the formula and processing technology of fructose and the alcohol-decomposing beverage of tea extract composition：Formula：Tea extract 3 ~
8kg, 90 ~ 95 kg of fructose syrup for being 78% containing fructose；Production technology is that tea extract and crystal diabetin are dissolved in can
It as in the clean water of beverage application, is uniformly mixed, the concentration of fructose is made to reach 8 ~ 10%, be packed as 150 ~ 250ml/ bottles, envelope
Dress to get.Alcohol-decomposing beverage prepared by the technique replaces crystal diabetin using fructose syrup, the concentration of fructose in fructose syrup
Can 42% ~ 90% range, to be containing 78% fructose syrup.
The fructose drunkenness dispelling tea and fructose sobering-up beverage prepared according to above example, it is drunk through animal it is demonstrated experimentally that
Have it is good relieve the effect of alcohol and sobering-up functions, the drunk rate of animal can be reduced, hence it is evident that shorten the drunk time of animal, it is long-term to some
The people to drink drinks, and when taking more slightly larger than the amount that they usually drink, drunk situation does not occur, practice confirms, with big
The fructose drunkenness dispelling tea and fructose sobering-up beverage prepared based on dosage fructose and tea extract can play and relieve the effect of alcohol and protect liver
Effect.
Claims (9)
1. the formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract.
2. the formula of the health food of the one group as described in claim 1 Soboring-up liver-protecting being made of fructose and tea extract and
Production technology, it is characterized in that preparing the formula and processing technology of fructose Soboring-up liver-protecting black tea is：Formula：Black tea extract 3~
10kg, 90 kg of crystal diabetin；Production technology is that first black tea is crushed is coarse powder, is added according to the ratio of solid-liquid ratio 1: 25
75% ethyl alcohol, is first extracted with ultrasonic extraction, ultrasonic power 200W, and Extracting temperature is 70 DEG C, extraction time 30
Min is filtered while hot, and filtrate recycling ethanol is simultaneously concentrated into relative density 1.30~1.32, is dried under reduced pressure, is ground into fine powder；Filter residue
It adds water boiling twice, 2 hours for the first time, second 1.5 hours, merges steaming liquid, filtering, filtrate is concentrated into relative density 1.30
~1.32 clear cream, is dried under reduced pressure, and is ground into fine powder, two kinds of fine powders is merged, by 3~10:90 ratio is mixed with crystal diabetin
Close uniform, be packed as 10~12g/ packets, aluminium film encapsulate to get.
3. the formula of the health food of the one group as described in claim 1 Soboring-up liver-protecting being made of fructose and tea extract and
Production technology, it is characterized in that preparing the formula and processing technology of fructose protect liver green tea is：Formula：3 ~ 10kg of green-tea extract,
3 ~ 10kg of taurine, 95 kg of crystal diabetin；Production technology is that green tea crushing is coarse powder, is steamed according to the ratio of solid-liquid ratio 1: 40
Distilled water, control Extracting temperature are 70 DEG C, extraction 90min, filtering, retain filtrate, and filter residue presses the extraction of preceding method once, retains filter again
Liquid merges filtrate, filtrate twice and is concentrated into the clear cream of relative density 1.30 ~ 1.32, is dried under reduced pressure, is ground into fine powder；Filter residue is pressed
The ethyl alcohol for taking care of the ratio addition 75% of liquor ratio 1: 20, being 70 DEG C in temperature makes heating and refluxing extraction, extraction time be 50 min,
It filters while hot, filtrate recycling ethanol is simultaneously concentrated into relative density 1.30 ~ 1.32, is dried under reduced pressure, is ground into fine powder；Two kinds of fine powders
Merge, is uniformly mixed, is packed as with crystal diabetin by the ratio of green-tea extract 3 ~ 10, taurine 3 ~ 10, crystal diabetin 85 ~ 95
10 ~ 12g/ packets, aluminium film encapsulation to get.
4. the formula of the health food of the one group as described in claim 1 Soboring-up liver-protecting being made of fructose and tea extract and
Production technology, it is characterized in that preparing the formula and processing technology of fructose oolong tea：Formula：3 ~ 10kg of oolong tea extract, sulphur
Octanoic acid 3 ~ 10kg, 85 ~ 95kg of crystal diabetin；It is coarse powder that production technology, which is oolong tea crushing, according to the ratio of solid-liquid ratio 1: 25
The ethyl alcohol of example addition 75%, is extracted, ultrasonic power 200W with ultrasonic extraction, and Extracting temperature is 70 DEG C, extraction time 30
Min is filtered while hot, and filtrate recycling ethanol is simultaneously concentrated into relative density 1.30 ~ 1.32, is dried under reduced pressure, is ground into fine powder；Filter residue is again
Add water boiling twice, 2 hours for the first time, second 1.5 hours, merges steaming liquid, filtering, it is density 1.30 that filtrate, which is concentrated into opposite,
~ 1.32 clear cream, is dried under reduced pressure, and is ground into fine powder, by oolong tea extract 3 ~ 10, lipoic acid 3 ~ 10, crystal diabetin 85 ~ 95
Ratio is uniformly mixed with crystal diabetin, is packed as 10 ~ 12g/ packets, aluminium film encapsulation to get.
5. the formula of the health food of the one group as described in claim 1 Soboring-up liver-protecting being made of fructose and tea extract and
Production technology, it is characterized in that preparing the formula and processing technology of fructose Pu'er tea is：Formula：3 ~ 10kg of Pu'er tea,
3 ~ 10kg of taurine, 3 ~ 10kg of lipoic acid, 85 ~ 95 kg of crystal diabetin；Production technology is that first Pu'er tea is crushed is coarse powder,
According to the ethyl alcohol of the ratio addition 75% of solid-liquid ratio 1: 25,40 min of refluxing extraction when temperature is 70 DEG C is filtered, filtrate while hot
Recycling ethyl alcohol is simultaneously concentrated into relative density 1.30 ~ 1.32, is dried under reduced pressure, is ground into fine powder；Filter residue adds water boiling twice, and first
Secondary 2 hours, second 1.5 hours, merge steaming liquid, filtering, filtrate is concentrated into the clear cream of relative density 1.30 ~ 1.32, and decompression is dry
It is dry, be ground into fine powder, by Pu'er tea 3 ~ 10, taurine 3 ~ 10, lipoic acid 3 ~ 10, the ratio of crystal diabetin 85 ~ 95 with
Crystal diabetin is uniformly mixed, and is packed as 10 ~ 12g/ packets, aluminium film encapsulate to get.
6. the formula of the health food of the one group as described in claim 1 Soboring-up liver-protecting being made of fructose and tea extract and
Production technology, it is characterized in that preparing the formula and processing technology of fructose Antialcoholic tea is：Formula：2 ~ 5kg of tea polyphenols, theanine 1
~ 2kg, 1 ~ 2kg of glutamic acid, 1 ~ 2kg of asparatate, 85 ~ 95 kg of crystal diabetin；Production technology is first each in formula
A ingredient is uniformly mixed with crystal diabetin, is ground into fine powder, is packed as 10 ~ 12g/ packets, aluminium film encapsulation to get.
7. the formula of the health food of the one group as described in claim 1 Soboring-up liver-protecting being made of fructose and tea extract and
Production technology, it is characterized in that preparing the formula and processing technology of fructose alcohol-decomposing beverage is：Formula：2 ~ 5kg of tea polyphenols, tea ammonia
Acid 1 ~ 2kg, 1 ~ 2kg of glutamic acid, 1 ~ 2kg of asparatate, 85 ~ 95 kg of crystal diabetin；Production technology is first in formula
Each ingredient and crystal diabetin be dissolved in the clean water that can be used as beverage application, be uniformly mixed, the concentration of fructose made to reach 8
~ 10%, be packed as 150 ~ 250ml/ bottles, encapsulation to get.
8. the formula of the health food of the one group as described in claim 1 Soboring-up liver-protecting being made of fructose and tea extract and
Production technology, it is characterized in that preparing the formula and processing technology for the alcohol-decomposing beverage that fructose is formed with tea extract is：Match
Side：3 ~ 8kg of tea extract, 90 ~ 95 kg of crystal diabetin；Production technology is that tea extract and crystal diabetin are dissolved in
It in the clean water that can be used as beverage application, is uniformly mixed, the concentration of fructose is made to reach 8 ~ 10%, be packed as 150 ~ 250ml/ bottles, envelope
Dress to get.
9. the formula of the health food of the one group as described in claim 1 Soboring-up liver-protecting being made of fructose and tea extract and
Production technology, it is characterized in that preparing the formula and processing technology for the alcohol-decomposing beverage that fructose is formed with tea extract is：Match
Side：3 ~ 8kg of tea extract, 90 ~ 95 kg of fructose syrup for being 78% containing fructose；Production technology be tea extract with
Crystal diabetin is dissolved in the clean water that can be used as beverage application, is uniformly mixed, so that the concentration of fructose is reached 8 ~ 10%, be packed as
150 ~ 250ml/ bottles, encapsulation to get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810468910.0A CN108720013A (en) | 2018-05-16 | 2018-05-16 | The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810468910.0A CN108720013A (en) | 2018-05-16 | 2018-05-16 | The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108720013A true CN108720013A (en) | 2018-11-02 |
Family
ID=63938425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810468910.0A Pending CN108720013A (en) | 2018-05-16 | 2018-05-16 | The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108720013A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111729016A (en) * | 2020-03-26 | 2020-10-02 | 华东师范大学 | White tea extract, preparation method and administration method thereof and application of white tea extract in olfactory injury repair |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1197377A (en) * | 1994-09-01 | 1998-10-28 | 格哈德·佐尔克 | Refreshing beverage |
| RU2281103C2 (en) * | 2003-12-26 | 2006-08-10 | Игорь Викторович Юдин | Method for production of sugar-based agents having antiviral and hepatoprotective action |
| CN101380390A (en) * | 2008-10-14 | 2009-03-11 | 中国科学院昆明植物研究所 | Preparation method of Pu-Er ripe tea standard extract PRC-001 and preparation method and use thereof |
| CN101766635A (en) * | 2008-12-31 | 2010-07-07 | 克科 | Composite for disintoxicating and sobering |
| CN101953825A (en) * | 2010-09-25 | 2011-01-26 | 万红贵 | Anti-alcohol composition and application thereof in preparation of health-care products |
| CN102113581A (en) * | 2010-12-31 | 2011-07-06 | 马艳荣 | Beverage for deinebriating |
| CN104997940A (en) * | 2014-04-25 | 2015-10-28 | 云南天士力帝泊洱生物茶集团有限公司 | Application of theabrownin in preparation of alcohol effect relieving drugs |
| CN106689530A (en) * | 2015-11-16 | 2017-05-24 | 威海长寿康海洋食品有限公司 | Honey and green tea combined formula and preparation method adopting same |
-
2018
- 2018-05-16 CN CN201810468910.0A patent/CN108720013A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1197377A (en) * | 1994-09-01 | 1998-10-28 | 格哈德·佐尔克 | Refreshing beverage |
| RU2281103C2 (en) * | 2003-12-26 | 2006-08-10 | Игорь Викторович Юдин | Method for production of sugar-based agents having antiviral and hepatoprotective action |
| CN101380390A (en) * | 2008-10-14 | 2009-03-11 | 中国科学院昆明植物研究所 | Preparation method of Pu-Er ripe tea standard extract PRC-001 and preparation method and use thereof |
| CN101766635A (en) * | 2008-12-31 | 2010-07-07 | 克科 | Composite for disintoxicating and sobering |
| CN101953825A (en) * | 2010-09-25 | 2011-01-26 | 万红贵 | Anti-alcohol composition and application thereof in preparation of health-care products |
| CN102113581A (en) * | 2010-12-31 | 2011-07-06 | 马艳荣 | Beverage for deinebriating |
| CN104997940A (en) * | 2014-04-25 | 2015-10-28 | 云南天士力帝泊洱生物茶集团有限公司 | Application of theabrownin in preparation of alcohol effect relieving drugs |
| CN106689530A (en) * | 2015-11-16 | 2017-05-24 | 威海长寿康海洋食品有限公司 | Honey and green tea combined formula and preparation method adopting same |
Non-Patent Citations (5)
| Title |
|---|
| 周圣弘 等: "《简明中国茶文化》", 31 July 2017, 武汉：华中科技大学出版社 * |
| 国家粮食局编: "《建设粮食产业强国实践与探索》", 31 January 2018, 北京：中国财富出版社 * |
| 张银仓: "废茶叶综合利用工业化生产工艺研究—茶多酚、茶多糖、茶氨酸及咖啡碱工业化生产", 《中国优秀硕士学位论文全文数据库（电子期刊） 工程科技Ⅰ辑》 * |
| 文杰: "茶多糖护肝降糖作用研究及茶多糖重复结构寡糖的合成", 《中国优秀硕士学位论文全文数据库（电子期刊） 工程科技Ⅰ辑》 * |
| 李大伟 等: "茶氨酸复合剂对酒精性肝损伤大鼠肝脏保护作用研究", 《中国茶叶加工》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111729016A (en) * | 2020-03-26 | 2020-10-02 | 华东师范大学 | White tea extract, preparation method and administration method thereof and application of white tea extract in olfactory injury repair |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101889679B (en) | Composition with disintoxicating and liver-protecting effects and application thereof in food and health-care food | |
| KR101717893B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| CN102764408B (en) | Dealcoholic preparation | |
| CN104107217A (en) | Composition For Preventing Or Treating Hangover | |
| CN106135891A (en) | A kind of health food to alcoholic liver injury with defencive function | |
| CN108404019A (en) | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance | |
| US20160199427A1 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| CN103191214B (en) | Preparation for relieving or neutralizing effect of alcohol and protecting liver | |
| CN103251698B (en) | Puerarin beverage with effects of dispelling alcoholism, protecting liver and protecting stomach and preparation method thereof | |
| JP2002012547A (en) | Saccharide decomposition-inhibiting agent, insulin secretion-inhibiting agent, and health beverage or food | |
| KR101093998B1 (en) | Functional composition for the prevention of hangover and improving liver function | |
| KR20100129571A (en) | Functional composition for improvement of sex and food having the same | |
| JP2016152817A (en) | Xanthine oxidase inhibitor | |
| KR101394358B1 (en) | Health composition relieving alcohol hangover | |
| CN103006922A (en) | Composition having function of relieving alcoholism to protect liver | |
| CN108720013A (en) | The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract | |
| KR100392876B1 (en) | A drink for eliminating a hangover and a method for producing the same | |
| KR101177888B1 (en) | Composition for Relieving and Preventing Hangover | |
| CN107441429A (en) | A kind of sobering-up composition and preparation method thereof | |
| KR20110132887A (en) | Composition for improving hepatic, stomachic function and curing hangover | |
| KR102080204B1 (en) | Clathrate compound of Schisandra chinensis extract and method for its production | |
| JP2011012021A (en) | Blood sugar-controlling composition | |
| KR20080035853A (en) | A composition having protective function from alcoholic hangover comprising dropwort extract as active ingredient and functional health food using the same | |
| US20240123019A1 (en) | Composition for treating or ameliorating liver disease and liver dysfunction comprising zizania latifolia extract | |
| CN109717437A (en) | One kind is relieved the effect of alcohol compound honey paste and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181102 |